ニュース

• Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
  14:00 - GlobeNewswire
•  
• Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
  13:00 - GlobeNewswire
•  
• Pixium Vision receives HealthTech Award for Prima System at the MedTech Forum
  12:00 - GlobeNewswire
•  
• Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
  00:40 - GlobeNewswire
•  
• Latest AMD Radeon Software Release Expands Remote Gaming Functionality and Enables New Features and Customization Capabilities
  20.04.2021 / 15:00 - GlobeNewswire
•  
• Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  16.04.2021 / 18:44 - GlobeNewswire
•  
• Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 
  16.04.2021 / 14:05 - GlobeNewswire
•  
• AMD to Report Fiscal First Quarter 2021 Financial Results
  15.04.2021 / 22:15 - GlobeNewswire
•  
• Dow closes above 34,000 pts, Nasdaq at record closing high
  15.04.2021 / 22:01 - TeleTrader
•  
• Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
  15.04.2021 / 14:00 - GlobeNewswire
•  
• CORSAIR Launches New AMD Ryzen™ 5000-Series Powered CORSAIR ONE a200 and 11th Gen Intel® Core™-Powered CORSAIR ONE i200 Gaming PCs
  13.04.2021 / 15:00 - GlobeNewswire
•  
• Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
  13.04.2021 / 13:00 - GlobeNewswire
•  
• OXURION NV to Present at Wet AMD and DME Drug Development Summit
  13.04.2021 / 07:30 - GlobeNewswire
•  
• AMD and Xilinx Stockholders Overwhelmingly Approve AMD’s Acquisition of Xilinx
  07.04.2021 / 18:49 - GlobeNewswire
•  
• Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
  07.04.2021 / 17:45 - GlobeNewswire